If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

July 27, 2010

More Hyperphosphatemia Clinical Trials

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

Sponsor and Collaborators
The University of Hong Kong

Contact
Contact: Angela YM Wang, MD, FRCP
852-28554111 ext 4949
aymwang@hku.hk

Principal Investigator
Angela YM Wang, MD, FRCP Queen Mary Hospital, University of Hong Kong

ClinicalTrials.gov Identifier
NCT00745589